NCT01741194已完成2 期
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Cerecin82 个研究点 分布在 1 个国家目标入组 418 人开始时间: 2013年3月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 418
- 试验地点
- 82
- 主要终点
- Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)
研究概览
简要总结
This study will evaluate the effects of daily dosing of AC-1204 on cognition, activities of daily living, resource utilization, quality of life, pharmacokinetic measures and safety among participants with mild to moderate Alzheimer's Disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 66 Years 至 90 Years（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Dementia status of mild to moderate
- •CT or MRI scan within 18 months prior to screening compatible with a diagnosis of probable Alzheimer's disease
- •Score on the Wechsler Memory Scale - Logical Memory II recall below a pre-determined cut-off, adjusted for education level
- •Confirmed apolipoprotein E genotype prior to randomization
- •Prior and current use of medication that corresponds with protocol requirements
- •Stable medical condition, with the exception of dementia, for at least 3 consecutive months prior to screening
- •No active suicidal thoughts within 6 months of screening, no active history of suicide attempt in the previous 2 years, no more than 1 lifetime suicide attempt, no serious suicidal risk
- •Able to comply with protocol testing and procedures for the duration of the study
- •Has a permanent caregiver (caregiver is not expected to change during the course of the study) who is willing to attend all visits, oversee the participant's compliance with protocol procedures and study medication administration, and report on the participant's status
- •Resides in the community (includes assisted living facilities, but excludes long-term care nursing facilities)
- •Both participant and caregiver have the ability to read and write in English or Spanish and have hearing, vision and physical abilities adequate to perform the assessments (corrective aids allowed)
- •Participant and caregiver have provided full written informed consent prior to the performance of any protocol-specified procedure. If participant is unable to provide informed consent due to cognitive status, provision of informed consent by cognitively intact legally acceptable representative (where this is in accordance with local laws, regulations and ethics committee policy)
- •Participant is able to ingest oral medication
排除标准
- •Current use, or use within 3 months of baseline, of medium-chain triglyceride-containing products
- •Use of any other investigational agent within 60 days prior to screening
- •Known allergy or hypersensitivity to milk or soy products
- •In the opinion of the investigator, presence or history of advanced, severe, progressive or unstable disease of any type that could interfere with protocol assessments or put the participant at particular risk
- •Any medical or neurological condition other than Alzheimer's disease that could explain the patient's dementia
- •History or clinical laboratory evidence of moderate congestive heart failure
- •Clinically significant ECG abnormalities at screening
- •History of new cardiovascular events within 6 months prior to baseline
- •History of or current psychiatric illness
- •Major depression as determined by Cornell Scale for Depression in Dementia
- •Insulin-dependent diabetics
- •Systolic blood pressure > 165 mmHg or diastolic blood pressure > 95 mmHg
- •Drop of 20 mm Hg systolic blood pressure or greater upon standing upright from a seated position within 3 minutes at screening
- •Clinically significant anemia at screening
- •Clinically significant renal disease or insufficiency at screening
- •Laboratory values for liver function tests > 2.5 times the upper limit of normal at screening or history of severe liver disease
- •Fasting triglycerides > 2.5 times the upper limit of normal at screening
- •Clinically significant B12 deficiency within 12 month prior to screening
- •Inflammatory bowel disease or peptic ulcer disease.
- •Participants with current or a history of (within the last 5 years) complicated reflux disease or severe GERD that is not well-controlled by medication.
- •Irritable bowel syndrome, diverticular disease (e.g., diverticulosis or diverticulitis), or chronic gastritis (exclusionary if there has been a diagnosis or an acute event within 5 years prior to Screening.)
- •Has donated ≥ 2 units of blood within the 2 months prior to screening
- •History of alcohol or drug abuse within 6 months prior to screening, or positive urine drug test at screening
- •Participant or caregiver is an immediate family member or employee of the clinical site, sponsor or sponsor's agents
- •An alternative cause for dementia other than Alzheimer's disease as determined by a required CT or MRI scan within 18 months prior to screening
- •History of neoplasm or malignancies within 5 years prior to screening, except for basal cell or squamous cell carcinoma of the skin
- •Clinically significant hypothyroidism as determined thyroid function testing at screening
- •Participant has scheduled or expected hospitalization and/or surgery during the course of the study
研究组 & 干预措施
AC-1204
Experimental
Powder formulation (40 g) mixed with 4-8 ounces of water, other liquid or soft food as preferred, and shaken or blended until fully mixed. Each dosing unit of AC-1204 contains 20 g of the active ingredient, caprylic triglyceride.
干预措施: AC-1204 (Drug)
Placebo
Placebo Comparator
Placebo is an isocaloric formulation prepared to be virtually identical to AC-1204 in appearance, odor and taste. Powdered formulation is mixed with 4-8 ounces of water, other liquid or soft food as preferred, and shaken or blended until fully mixed.
干预措施: Placebo (Drug)
结局指标
主要结局
Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)
时间窗: 26 weeks
APOE(-) participants
次要结局
- Clock Draw Interpretation Scale (CDIS)(8 and 17 weeks)
- Alzheimer's Disease Co-operative Study - Clinical Global Impression of Change (ADCS-CGIC)(26 weeks)
- Quality of Life - Alzheimer's Disease (QoL-AD)(26 weeks)
- Resource Utilization in Dementia (RUD-Lite)(26 weeks)
- Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)(8 and 17 weeks)
- Incidence of treatment-emergent adverse events(26 weeks)
- Alzheimer's Disease Co-operative Study - Activities of Daily Living (ADCS-ADL)(26 weeks)
研究者
研究点 (82)
Loading locations...
相似试验
已完成
2 期
Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive DisorderDepressive Disorder, MajorNCT01564862Takeda602
已完成
3 期
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)Pulmonary Disease, Chronic ObstructiveNCT02006732Boehringer Ingelheim809
已完成
3 期
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)Pulmonary Disease, Chronic ObstructiveNCT01964352Boehringer Ingelheim813
已完成
4 期
Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing RegimensMigraineNCT05217927Pfizer1,415
已完成
3 期
Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive EsophagitisErosive EsophagitisNCT02456935HK inno.N Corporation280